Obesity Clinical Trial
Official title:
A Pilot Study to Assess the Tolerability of a Single, Ascending Dose of a Non-digestible Carbohydrate in Healthy Volunteers
This is an initial pilot study to assess and investigate if any adverse symptoms occur (and also the severity of any symptoms) after consuming a food-grade Cellodextrin preparation. Volunteers will attend a short (around 30mins) medical screening visit, to make sure they are suitable to take part in the study. They will then attend 4 study visits (separated by at least a week) for around 9.5 hours each time. During the study visits 10, 20, 30, or 50g of Cellodextrin will be given as a single oral dose, in a milkshake drink, and any symptoms experienced will then be monitored via questionnaires during the study day and for the next 60 hrs, dietary intake will also be measured over this time.
Cellodextrins are small-chain, non-absorbable, oligosaccharides that are produced from the
incomplete hydrolysis of insoluble cellulose. Like other oligosaccharides they escape
digestion in the small intestine as the human gut lacks the enzymes required to hydrolyse the
β-links formed among the units of monosaccharides. However, Bifidobacterium in the
caeco-colon possess the enzymes β-fructosidase and β-galactosidase which are needed to
breakdown the carbohydrate chains to their constituent sugars, this serves the bacteria by
providing energy for proliferation and also produces gases (Hydrogen, Carbon dioxide, and
Methane, which are metabolically useless to the host), and short chain fatty acids (SCFA).
This breakdown supplies an available energy estimated to be 1.5-2kcal/g, in comparison
digestible carbohydrate produces 4kcal/g of available energy.
The prevalence of overweight and obesity is an increasing issue in the developed world and
reduction of energy intake remains at the heart of the main treatments for obesity. Due to
this there is an interest in identifying food ingredients that will combat dietary
overconsumption. By replacing some of the digestible carbohydrates with non-digestible
oligosaccharides it could be possible to reduce the caloric load of food by approximately
2kcal/g of carbohydrate, but still keep the taste and 'mouth-feel' of these reduced calorie
products. Further benefits of the use of non-digestible oligosaccharides against dietary
overconsumption include the contribution that these compounds could have on reducing appetite
and voluntary food intake, which could further improve energy intake regulation.
Oligosaccharides may increase satiety by bulking, by slowing gastric emptying, or by
increasing production of Peptide-yy (PYY) and Glucagon like peptide-1 (GLP-1). The latter has
been demonstrated in-vitro, where butyrate, one of the SCFA's produced in oligosaccharide
break-down, increased PYY and Proglucagon production in rat epithelial cells. Little work has
been done on the potential oligosaccharide effects on appetite. and assessment of the
appetite effects and energy regulation potential of Cellodextrin in humans is even more
limited. However, before studies to investigate this can be carried out, it is important to
assess any gastro-intestinal disturbances that may occur at the doses which would be
required.
The recommendation for total fibre intake is 18g/day in the United Kingdom (UK) although the
actual UK average intake is lower than this, at an average of 13-15g/day. It is not known
what the average daily oligosaccharide intake is in the UK, or whether the oligosaccharides
are included in the total fibre estimates. However, because they are not digested within the
small intestine, they can have a laxative effect, increasing the ease and/or frequency of
laxation and excess intakes may cause diarrhoea and other gastrointestinal symptoms such as
flatulence, bloating and abdominal discomfort. Intolerance symptoms can be due to the osmotic
effect and/or fermentation; the osmotic effect may cause abdominal pain and eventually
diarrhoea if the capacity of the colon to absorb water is exceeded. Moreover, fermentation
produces gases that may also induce abdominal pain, bloating and excessive flatus. The
tolerance of non-digestible oligosaccharides is usually very good, although the tolerance
threshold depends on the type of oligosaccharide, the timing of consumption (e.g. after
fasting or after a meal) and also individual factors such as absorption capacities, motility
patterns, colonic responses and intestinal sensitivity. Polydextrose has been found to be
tolerated at doses of 50g/day, resistant starch has a similar tolerability at acceptable
doses of 45g/day, whereas galacto-oligosaccharide consumption of over 20g/day and
fructo-oligosaccharide consumption of over 40g/day have been reported to cause diarrhoea.
The aim is to investigate initially whether Cellodextrin induces gastrointestinal symptoms in
a UK cohort of healthy men and women and to what extent. This information can then be used to
inform future volunteers as to the relative risks of developing these gastrointestinal
problems and the severity of symptoms experienced. A descriptive pilot study will be carried
out. Twelve healthy individuals (6 males and 6 females, 18-40y, with a BMI between 18 and
30kg/m2) will be recruited. Interested individuals will contact the investigators and be sent
a copy of the information sheet before attending a medical screening. At the medical
screening a full explanation of the study will be given and informed consent gained. A
medical screening questionnaire will be administered, blood pressure measurements made and a
10ml blood sample will be taken via venepuncture by suitably qualified staff (analysed for
full blood count, urea and electrolytes). If suitable, participants will attend the
laboratory for up to 4 visits and to provide a fecal sample (for microbiota assessment) prior
to attending the first study visit. Participants will arrive at the laboratory around 8am,
fasted from midnight the night before, and will then complete a series of appetite and
gastro-intestinal symptom questionnaires. They will be asked to empty their bladder and a
24hr urine collection will be started. After resting on a hospital bed for 15 min, a cannula
will be sited for blood sampling. The participant will then consume 10, 20, 30 or 50g of
Cellodextrin in a milkshake drink. They will repeat the questionnaires every 30 minutes for
180 minutes with 1ml of blood taken from the cannula every 15 minutes over this time. The
cannula will then be removed and a standard snack given to stimulate gut motility and
questionnaires (as before) will be completed after 210 and 240 minutes. A low fiber sandwich
lunch will be provided at 240mins,and during the following 2 hours, questionnaires will be
administered every 30 minutes and then again at 420 and 480mins. Participants will be given a
diet and symptom diary to complete over the rest of the day and the following 48hrs after
each study visit. Feedback forms will be administered if a participant withdraws from or
completes the study. Further fecal samples will be collected between 24 and 48hrs after
consumption of the 30g and 50g dose.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |